Tandutinib
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80071765
CAS NO.387867-13-2
Purity 98%
MDL NumberMFCD09954147
Molecular FormulaC31H42N6O4
Molecular Weight562.711
Melting point: 177-178°C
| Item | Information |
|---|---|
| Mechanism of Action | Tandutinib (MLN518) is a selective inhibitor of FLT3 (FMS-like tyrosine kinase 3), c-Kit, and PDGFR (platelet-derived growth factor receptor) tyrosine kinases. It inhibits the autophosphorylation of these receptors, thereby reducing cellular proliferation and inducing apoptosis. |
| Indications | – Investigated for the treatment of acute myeloid leukemia (AML), particularly in patients with FLT3 mutations.<br>- Potential use in other cancers where FLT3, c-Kit, and PDGFR are involved. |
| Clinical Development | – Phase I/II clinical trials have been conducted, with some showing promising results in extending survival in animal models.<br>- The drug has been granted fast-track status by the FDA for AML treatment. |
| Pharmacokinetics | – Tandutinib has the ability to cross the blood-brain barrier, which is advantageous for targeting central nervous system involvement in cancers. |
| Storage Conditions | – Powder form: -20°C for 3 years.<br>- In solvent: -80°C for 1 year. |
| Formulation | Available as a powder for research use. |
| Research Applications | – Widely used in preclinical studies to investigate the role of FLT3, c-Kit, and PDGFR in cancer progression.<br>- Studied for its potential in overcoming resistance to other FLT3 inhibitors |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
